Gheorghe Doros, PhD
Professor
Boston University School of Public Health
Dept of Biostatistics

PhD, Yale University
MA, Yale University
MS, University of Bucharest



Gheorghe Doros is Professor of Biostatistics and director of the Biostatistics Consulting Group. He received his PhD in Statistics from Yale University and joined BUSPH’s Department of Biostatistics in 2006 after spending two years at Eli Lilly, as a member of that company's Drug Discovery and Toxicology department. Dr. Doros’s research on methodological approaches and strategies has been concentrated in the area of clinical trials, more specifically on Bayesian approaches to clinical trials and the area of placebo response in clinical trials. The outcome of his work has been a corner stone in developing a host of collaborations with outstanding faculty, clinicians, and researchers at the Boston University Medical Campus and at other institutions. These productive collaborations have resulted in several federally funded grants. Dr. Doros authored and co-authored many peer-reviewed publications of original and innovative research which has had a major impact on the field. On the majority of publications, Dr. Doros is the lead statistician author. He demonstrated continuing record of multidisciplinary research that has had a major impact on the rapidly changing field. His publications on clinical trials; most proposing the design, analysis and new methodologies or of significant contributions to this field.
Dr. Doros is a very active and effective teacher and mentor in the department of Biostatistics. His teaching philosophy is to pursue an active approach to learning and to engage students to think critically. He taught core and elective courses for Master and PhD-level courses. The excellent course evaluations he received attests to his ability in engaging students in active learning. Dr. Doros has been awarded the excellence in teaching three times in three years.
On a national level, Dr. Doros has served as an Associate Editor for the BioMed Central’s journal Trials and as a reviewer for a number of academic journals. He served as a member of the merit review subcommittee for Epidemiology of the Department of Veteran Affairs and a member NHLBI-Ancillary Studies in Clinical Trials between 2012 and 2014. He has served as a statistical expert on a number of Independent Data Monitoring Committee(IDMC) for clinical trials and clinical programs. He served or seves as a senior consultant on multicenter trials and/or programs for the following organizations Pfizer, Takeda, Avanir, Sarepta and Children's Hospital.

Boston Medical Center




Gheorghe Doros, PhD: Statistical research in clinical trials (Baim Institute for Clinical Research)
09/01/2017 - 08/31/2018 (PI)
Baim Institute for Clinical Research

Personnel Agreement for Research Services of Gheorghe Doros
05/01/2016 - 08/31/2018 (PI)
VA Boston Healthcare System


Gheorghe Doros, PhD (faculty): Statistical research in clinical trials (Harvard Clinical Research Institute)
09/01/2016 - 08/31/2017 (PI)
Harvard Clinical Research Institute


Personnel agreement for research services of Gheorghe Doros
07/01/2012 - 05/31/2013 (PI)
VA Boston Healthcare System


Personnel Agreement for Research Services of Gheorghe Doros
08/01/2009 - 03/31/2012 (PI)
VA Boston Healthcare System


Personnel Agreement for Research Services of Gheorghe Doros
06/01/2008 - 03/31/2012 (PI)
VA Boston Healthcare System


Lower Extremity Muscle Power and Function in the Elderly
06/15/2005 - 05/31/2010 (PI)
Tufts University NIH NIA




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018 May 14; 39(19):1726-1735a. PMID: 29668889.
     
  2. Inagaki E, Farber A, Siracuse JJ, Mell MW, Rybin DV, Doros G, Kalish J. Routine Use of Ultrasound Guidance in Femoral Arterial Access for Peripheral Vascular Intervention Decreases Groin Hematoma Rates in High-Volume Surgeons. Ann Vasc Surg. 2018 Apr 13.View Related Profiles. PMID: 29655812.
     
  3. Inagaki E, Farber A, Kalish JA, Eslami MH, Siracuse JJ, Eberhardt RT, Rybin DV, Doros G, Hamburg NM. Outcomes of Peripheral Vascular Interventions in Select Patients With Lower Extremity Acute Limb Ischemia. J Am Heart Assoc. 2018 Apr 12; 7(8).View Related Profiles. PMID: 29650705.
     
  4. Rosman NP, Vassar R, Doros G, DeRosa J, Froman A, DiMauro A, Santiago S, Abbott J. Association of Prenatal Ultrasonography and Autism Spectrum Disorder. JAMA Pediatr. 2018 Apr 01; 172(4):336-344.View Related Profiles. PMID: 29435580.
     
  5. Eslami MH, Reitz KM, Rybin DV, Doros G, Farber A. Improved access to health care in Massachusetts after 2006 Massachusetts Healthcare Reform Law is associated with a significant decrease in mortality among vascular surgery patients. J Vasc Surg. 2018 Mar 31.View Related Profiles. PMID: 29615354.
     
  6. Januzzi JL, Chen-Tournoux AA, Christenson RH, Doros G, Hollander JE, Levy PD, Nagurney JT, Nowak RM, Pang PS, Patel D, Peacock WF, Rivers EJ, Walters EL, Gaggin HK. N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. J Am Coll Cardiol. 2018 Mar 20; 71(11):1191-1200. PMID: 29544601.
     
  7. Kandzari DE, Mauri L, Koolen JJ, Doros G, Waksman R. Bioresorbable polymer drug-eluting stents - Authors' reply. Lancet. 2018 Mar 10; 391(10124):936-937. PMID: 29536855.
     
  8. Lubitz SA, Khurshid S, Weng LC, Doros G, Keach JW, Gao Q, Gehi AK, Hsu JC, Reynolds MR, Turakhia MP, Maddox TM. Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. Am Heart J. 2018 Jun; 200:24-31. PMID: 29898845.
     
  9. Ibrahim NE, Song Y, Cannon CP, Doros G, Trebnick A, Russo P, Ponirakis A, Alexanian C, Januzzi JL. Retraction notice to Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry® [International Journal of Cardiology 254 (2018) 222-223]. Int J Cardiol. 2018 03 01; 254:R1. PMID: 29752128.
     
  10. Ibrahim N, Gaggin HK, Turchin A, Patel HK, Song Y, Trebnick A, Doros G, Maya JF, Cannon CP, Januzzi JL. Heart Rate, Beta Blocker Use, and Outcomes of Heart Failure with Reduced Ejection Fraction. Eur Heart J Cardiovasc Pharmacother. 2018 Feb 27. PMID: 29490032.
     
Showing 10 of 189 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 185 publications over 15 distinct years, with a maximum of 31 publications in 2017

YearPublications
20041
20051
20062
20077
20082
200910
20109
201114
20128
201315
201420
201530
201620
201731
201815
Contact for Mentoring:


801 Massachusetts Ave Crosstown Center
Boston MA 02118
Google Map


Doros's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department